钠-葡萄糖协同转运蛋白2抑制剂是否增加泌尿植入物再干预风险
基于TriNetX数据库的回顾性队列研究,比较服用SGLT2i与未服用的成年男性在接受人工尿道括约肌或充气式阴茎假体后的再干预风险。经倾向性评分匹配后,IPP组319例、AUS组83例。服用SGLT2i的IPP患者总体并发症风险较低(10.6% vs 16.1%,RR 0.66,P=0.049),AUS并发症风险及两种植入物的感染和再干预风险均相似。
要点
- 服用SGLT2i的IPP患者总体并发症风险低于未服用者(10.6% vs 16.1%,RR 0.66,P=0.049)。
- SGLT2i与AUS并发症风险及两种植入物的感染和再干预风险均无显著差异。
- 服用SGLT2i的患者可能可以安全接受泌尿植入物。
核心结论
- 服用SGLT2i的患者可能可以安全接受泌尿植入物。
- 服用SGLT2i的IPP患者并发症风险较低,IPP和AUS的感染和再干预率均相似。
研究设计与样本
- 查询TriNetX数据库的回顾性队列研究,纳入接受人工尿道括约肌(AUS)或充气式阴茎假体(IPP)的成年男性患者。
- 比较服用SGLT2i与未服用SGLT2i的患者,使用年龄、体重指数、糖尿病、吸烟史和前列腺切除史进行倾向性评分匹配。
- 分析于2022年11月28日进行;匹配后IPP组319例、AUS组83例,两组合并症特征相似。
主要发现
- 服用SGLT2i的IPP患者总体并发症风险低于未服用者(10.6% vs 16.1%,RR 0.66,P=0.049)。
- AUS的并发症风险以及两种植入物的感染或再干预风险在服用与未服用SGLT2i的患者间相似。
临床怎么用
- 作者认为服用SGLT2i的患者可能可以安全接受泌尿植入物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To understand whether patients taking sodium-glucose co-transporter 2 inhibitors (SGLT2i) would be at a similar risk of genitourinary device infection or failure as patients not taking these medications. METHODS: We queried the TriNetX database for all adult male patients undergoing artificial urinary sphincter (AUS) or inflatable penile prosthesis (IPP) and compared patients taking SGLT2i against those not. Cohorts and outcomes were defined using current procedural terminology and International Classification of Diseases (ICD-10) codes. We used Age, body mass index, diabetes, smoking history and history of prostatectomy to generate propensity score matching. Our primary outcome was need for reintervention after implantation based on current procedural terminology codes. Secondary outcomes included infection rate and overall complication rate based on ICD-10 codes. Analytics were performed via TriNetX which calculated risk ratios. RESULTS: Analyses were run on November 28, 2022. After propensity score matching, there were 319 and 83 patients in each IPP and AUS cohort and comorbidity profiles were similar. Patients with an IPP on an SGLT2i were at a lower risk of overall complication (10.6% vs 16.1%, RR 0.66, P = .049). There was similar rates for AUS and risk of complication and for either implant on risk of infection or reintervention. CONCLUSION: Patients taking SGLT2is may be safely offered urologic implants. Patients taking an SGLT2 had a lower risk of complication for IPP, and there were similar rates of infection and reintervention for both IPP and AUS.
引用
- Prebay ZJ, Foss H, Ebbott D, et al. Do Sodium-Glucose Co-Transporter 2 Inhibitors Increase the Risk of Urologic Implant Reintervention? Urology. 2023. PMID: 36754235. doi:10.1016/j.urology.2023.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。